Erlotinib Hydrochloride 150 mg Tablets are an oral targeted anticancer medication belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor class.
It acts by reversibly inhibiting the phosphorylation of EGFR, blocking signal transduction pathways that promote cancer cell proliferation, angiogenesis, and survival.
Composition
Each film‑coated tablet contains:
Erlotinib Hydrochloride equivalent to Erlotinib …… 150 mg
Indications
First‑line, maintenance, or subsequent treatment of advanced non‑small cell lung cancer (NSCLC) with EGFR‑activating mutations.
In combination with other agents, for the treatment of metastatic pancreatic cancer.
Key Features
Oral targeted therapy with high selectivity for EGFR
Once‑daily dosing, convenient administration
Established efficacy and safety profile
Improved tolerability compared to conventional chemotherapy
Manufactured under strict GMP standards
Complies with international pharmacopoeial requirements
Full regulatory dossiers available for global registration
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
This is a prescription‑only medicine for use under the supervision of an oncologist.
May cause skin reactions, diarrhea, and interstitial lung disease; monitor closely during treatment.
Contraindicated in patients with hypersensitivity to erlotinib or any excipient.
